Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study August 12, 2024
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing August 8, 2024